Trillium Therapeutics Inc., of Toronto, said it advanced TTI-621, an SIRPa-IgG1 Fc fusion protein, from dose escalation into phase Ib cohort expansion enrollment in patients with advanced hematologic malignancies. Read More
Celldex Therapeutics Inc., of Hampton, N.J., said it has inked an agreement to acquire privately held Kolltan Pharmaceuticals Inc., of New Haven, Conn. Read More
Alkermes plc, of Dublin, reported that its total revenues for the third quarter of 2016 were $180.2 million compared to $152.7 million for the same period in 2015. Read More
Cidara Therapeutics Inc., of San Diego, has entered an agreement with Square 1 Bank, a division of Pacific Western Bank, for a $20 million credit facility. Read More
The world had to wait for them about a month longer than expected, but Palatin Technologies Inc.'s positive phase III data with bremelanotide in premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) should turn up the heat on already busy partnering talks. Read More
Leo Pharma A/S is again raising its bet on the promise of biologics to address important skin diseases, dealing in Morphosys AG and its Ylanthia antibody platform for a multi-target deal. The collaboration could yield multiple new dermatology therapies and milestone payments for Morphosys of up to €111.5 million (US$123.9 million) per program. Read More
LONDON – Four months from the referendum vote to leave the EU and – with the exception of a "commercially confidential" sweetheart deal with the Japanese car manufacturer Nissan – no company or sector is any clearer about the terms on which the U.K. government will seek to negotiate Brexit. Read More
Avexis Inc. is preparing for a David-and-Goliath showdown with Biogen Inc. and its partner, Ionis Pharmaceuticals Inc., after the FDA green-lighted the design of a pivotal trial for the upstart's gene therapy candidate, AVXS-101, in infants and children with spinal muscular atrophy (SMA) type 1. Read More
What a difference a few days and an FDA review can make. A week ago, Cempra Inc. (NASDAQ:CEMP) was trading just shy of $24. Wednesday, it closed at $7.30, down 60.9 percent in the company's heaviest day of trading ever. Read More
